Data on Non-Small Cell Lung Cancer Discussed by Researchers at Second Affiliated Hospital of Chongqing Medical University (Safety and effectiveness of localized lung resection combined with neoadjuvant chemotherapy in the treatment of stage ...)
By a News Reporter-Staff News Editor at Drug Week A new study on Oncology - Non-Small Cell Lung Cancer is now available. According to news reporting from Chongqing, People's Republic of China, by NewsRx journalists, research stated, "This study was conducted to evaluate the safety and effectiveness of localized lung resection combined with neoadjuvant chemotherapy in the treatment of stage I-II non-small cell lung cancer (NSCLC). A total of 88 patients, who were admitted to our hospital for first diagnosis and treatment, were selected."
The news correspondents obtained a quote from the research from the Second Affiliated Hospital of Chongqing Medical University, "The patients were divided into control group (n=40 cases) and observation group (n=48 cases) according to the last digit of the admission number. The control group was treated with minimally invasive localized lung resection by thoracoscope. The observation group underwent the same procedure combined with two cycles of systemic neoadjuvant chemotherapy before the surgery was adopted in the observation group. The effects of both treatments were compared. The operation time, intraoperative blood loss and postoperative drainage volume of observation group were significantly lower than those of the control group (p <0.05). The surgical resection rate and margin negative rate of observation group were higher than those of control group, while the occurrence rate of complications was lower than that of control group; results were statistically significant (p <0.05). The serum neutrophil gelatinase associated lipocalin (lipocalin-2/NGAL), matrix metalloproteinase-9 (MMP-9) and carcinoembryonic antigen (CEA) levels of two groups after the treatment were lower than those before; however, levels in the observation group exhibited a distinct decrease. The difference has statistical significance (p <0.05). The follow-up time of two groups was 3-38 months and the median time was 20.5 months. The tumor survival period of observation group was not prolonged, however, the survival rate and quality rate of life were enhanced; the difference has statistical significance (p <0.05)."
According to the news reporters, the research concluded: "Localized lung resection combined with neoadjuvant chemotherapy can effectively improve the surgical effect of stage I-II NSCLC, prolong the survival period, enhance the survival rate, decrease the occurrence rate of complications and reduce the tumor related factors lipocalin-2, MMP-9 and CEA levels."
For more information on this research see: Safety and effectiveness of localized lung resection combined with neoadjuvant chemotherapy in the treatment of stage I-II non-small cell lung cancer. Oncology Letters, 2017;13(4):2344-2348 (see also Oncology - Non-Small Cell Lung Cancer).
Our news journalists report that additional information may be obtained by contacting B. Zhu, Dept. of Cardiothoracic Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, People's Republic of China. Additional authors for this research include J. Yang, P. Zhang, L. Shen, X. Li and J. Li.
Keywords for this news article include: Asia, Oncology, Chongqing, Lipocalins, Chemotherapy, Lung Neoplasms, Carrier Proteins, Drugs and Therapies, People's Republic of China, Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC